Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7% - Time to Buy?

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) traded up 5.7% during mid-day trading on Monday . The company traded as high as $4.01 and last traded at $3.87. 2,159,066 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 32,192,027 shares. The stock had previously closed at $3.66.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. HC Wainwright lifted their target price on Sana Biotechnology from $8.00 to $11.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. TD Cowen raised Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday, January 8th. Finally, JMP Securities cut Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Sana Biotechnology currently has an average rating of "Moderate Buy" and an average price target of $14.25.

Sana Biotechnology Stock Down 5.5 %

The business has a 50-day moving average of $2.40 and a 200-day moving average of $4.03. The stock has a market cap of $772.51 million, a price-to-earnings ratio of -2.47 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. Equities analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Remove Ads

Insider Activity at Sana Biotechnology

In other news, insider Fmr Llc sold 290,912 shares of the company's stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total value of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 31.10% of the company's stock.

Institutional Investors Weigh In On Sana Biotechnology

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its holdings in shares of Sana Biotechnology by 26.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company's stock worth $2,357,000 after acquiring an additional 90,423 shares in the last quarter. Rhumbline Advisers lifted its holdings in Sana Biotechnology by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 181,903 shares of the company's stock worth $993,000 after buying an additional 25,056 shares in the last quarter. Arizona State Retirement System lifted its holdings in Sana Biotechnology by 36.7% during the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company's stock worth $202,000 after buying an additional 9,940 shares in the last quarter. XTX Topco Ltd acquired a new position in Sana Biotechnology during the 2nd quarter worth $100,000. Finally, Ensign Peak Advisors Inc acquired a new position in Sana Biotechnology during the 2nd quarter worth $372,000. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.